Zoetis Inc. $ZTS Shares Sold by Level Four Advisory Services LLC

Level Four Advisory Services LLC lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 50.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,188 shares of the company’s stock after selling 4,274 shares during the period. Level Four Advisory Services LLC’s holdings in Zoetis were worth $613,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Halbert Hargrove Global Advisors LLC grew its position in Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares during the period. NewSquare Capital LLC raised its holdings in shares of Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares during the period. Financial Consulate Inc. acquired a new position in shares of Zoetis in the 3rd quarter valued at about $39,000. SJS Investment Consulting Inc. lifted its stake in shares of Zoetis by 1,606.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after purchasing an additional 257 shares in the last quarter. Finally, TruNorth Capital Management LLC purchased a new stake in shares of Zoetis during the 3rd quarter worth about $42,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ZTS. Piper Sandler reaffirmed a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Morgan Stanley set a $160.00 target price on shares of Zoetis in a report on Thursday, December 18th. William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Monday. Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, January 28th. Finally, HSBC set a $140.00 target price on Zoetis in a research note on Wednesday, December 10th. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $152.91.

Zoetis Stock Performance

Zoetis stock opened at $121.54 on Friday. The stock has a 50 day moving average of $126.06 and a 200-day moving average of $133.20. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.00. The stock has a market cap of $51.31 billion, a P/E ratio of 20.19, a price-to-earnings-growth ratio of 1.87 and a beta of 0.95. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio is 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.